Androgen Replacement Therapy Market, by Product Type (Testosterone Creams/Gels, Testosterone Patches, Testosterone Injections, Testosterone Implants, and Testosterone Tablets/Capsules/Gums), by Active Ingredient Type (Testosterone, Methyl Testosterone, Te

Androgen Replacement Therapy Market, by Product Type (Testosterone Creams/Gels, Testosterone Patches, Testosterone Injections, Testosterone Implants, and Testosterone Tablets/Capsules/Gums), by Active Ingredient Type (Testosterone, Methyl Testosterone, Testosterone Undecanoate, Testosterone Enanthate, and Testosterone Cypionate), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies),  and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Androgen replacement therapy (ART), often referred to as testosterone replacement therapy (TRT), is a form of hormone therapy, in which androgens, often testosterone, are replaced. ART is often prescribed to counter the effects of male hypogonadism. It typically involves the administration of testosterone through injections, skin creams, patches, gels, or subcutaneous pellets. Testosterone replacement therapy is a promising technology for improving symptoms of hypogonadism and to raise the testosterone level. Furthermore, benefits related to application of testosterone replacement therapy include an increase in muscle tissue, overall surge in energy, and significant decrease in depression symptoms.
Market Dynamics
The androgen replacement therapy market is expected to witness growth during the forecast period, owing to the increasing number of product launches in the market. For instance, n November 2018, Antares Pharma, Inc. announced the commercial launch of XYOSTED, a subcutaneous injection of testosterone enanthate. XYOSTED was launched in three dosage strengths, 50 mg, 75 mg and 100 mg and is indicated for testosterone replacement therapy.
Key players are entering long term collaborations and agreements, which is expected to propel growth of the global androgen replacement therapy market during the forecast period. For instance, in June 2019, AbbVie, Inc. acquired Allergan, a global pharmaceutical company, in a cash and stock transaction for a transaction equity value of around US$ 63 billion, based on the closing price of AbbVie's common stock of US$ 78.45 on June 24, 2019. As a result of this acquisition, Abbivie, Inc. enhanced its long-term R&D funding capacity, allowing for continued investment and expand its product portfolio.
However, the side effects caused due to androgen replacement therapy are expected to hamper the androgen replacement therapy market growth. The side effects from the androgen replacement therapy include chest pain, shortness of breath or trouble breathing, weakness in one part or one side of the body, slurred speech, sleep apnea, increased cholesterol levels, and increased blood pressure. For instance, in 2015, the U.S. FDA issued a warning about potential cardiovascular risks such as heart attack and stroke resulting from testosterone therapy.
Key features of the study:
This report provides an in-depth analysis of global androgen replacement therapy market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022 - 2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global androgen replacement therapy market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study include AbbVie, Inc., Bayer AG, Endo Pharmaceuticals, Plc., Eli Lilly and Company, Kyowa Kirin International Plc., Novartis International AG, Pfizer Inc., Clarus Therapeutics, Inc., Perrigo Company Plc, Acerus Pharmaceuticals Corporation, Sawai pharmaceutical Co., Ltd., Reddy's Laboratories, Sun Pharmaceutical Industries Ltd., and Simple Pharma.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global androgen replacement therapy market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision making through various strategy matrices used in analyzing the androgen replacement therapy market
Detailed Segmentation:
Global Androgen Replacement Therapy Market, By Product Type:
Testosterone Creams/Gels
Testosterone Patches
Testosterone Injections
Testosterone Implants
Testosterone Tablets/Capsules/Gums
Global Androgen Replacement Therapy Market, By Active Ingredient Type:
Testosterone
Methyl Testosterone
Testosterone Undecanoate
Testosterone Enanthate
Testosterone Cypionate
Global Androgen Replacement Therapy Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Androgen Replacement Therapy Market, By Region:
North America
By Product Type:
Testosterone Creams/Gels
Testosterone Patches
Testosterone Injections
Testosterone Implants
Testosterone Tablets/Capsules/Gums
By Active Ingredient Type:
Testosterone
Methyl Testosterone
Testosterone Undecanoate
Testosterone Enanthate
Testosterone Cypionate
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.S.
Canada
Latin America
By Product Type:
Testosterone Creams/Gels
Testosterone Patches
Testosterone Injections
Testosterone Implants
Testosterone Tablets/Capsules/Gums
By Active Ingredient Type:
Testosterone
Methyl Testosterone
Testosterone Undecanoate
Testosterone Enanthate
Testosterone Cypionate
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Product Type:
Testosterone Creams/Gels
Testosterone Patches
Testosterone Injections
Testosterone Implants
Testosterone Tablets/Capsules/Gums
By Active Ingredient Type:
Testosterone
Methyl Testosterone
Testosterone Undecanoate
Testosterone Enanthate
Testosterone Cypionate
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
Asia Pacific
By Product Type:
Testosterone Creams/Gels
Testosterone Patches
Testosterone Injections
Testosterone Implants
Testosterone Tablets/Capsules/Gums
By Active Ingredient Type:
Testosterone
Methyl Testosterone
Testosterone Undecanoate
Testosterone Enanthate
Testosterone Cypionate
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
Middle East
By Product Type:
Testosterone Creams/Gels
Testosterone Patches
Testosterone Injections
Testosterone Implants
Testosterone Tablets/Capsules/Gums
By Active Ingredient Type:
Testosterone
Methyl Testosterone
Testosterone Undecanoate
Testosterone Enanthate
Testosterone Cypionate
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
GCC
Israel
Rest of Middle East
Africa
By Product Type:
Testosterone Creams/Gels
Testosterone Patches
Testosterone Injections
Testosterone Implants
Testosterone Tablets/Capsules/Gums
By Active Ingredient Type:
Testosterone
Methyl Testosterone
Testosterone Undecanoate
Testosterone Enanthate
Testosterone Cypionate
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
AbbVie, Inc.*
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Bayer AG
Endo Pharmaceuticals, Plc.
Eli Lilly and Company
Kyowa Kirin International Plc.
Novartis International AG
Pfizer Inc.
Clarus Therapeutics, Inc.
Perrigo Company Plc
Acerus Pharmaceuticals Corporation
Sawai pharmaceutical Co., Ltd.
Reddy's Laboratories
Sun Pharmaceutical Industries Ltd.
Simple Pharma
“*” marked represents similar segmentation in other categories in the respective section.